We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Bevespi Aerosphere

News List

Bevespi Aerosphere approved in China for patients with COPD americanpharmaceuticalreview
May 26, 2020
AstraZeneca’s Bevespi Aerosphere (glycopyrronium/formoterol fumarate) has been approved in China as a maintenance treatment to relieve symptoms in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
AZ’s new COPD inhaler Bevespi Aerosphere approved in EU pharmaphorum
December 24, 2018
AstraZeneca’s new inhaler Bevespi Aerosphere (glycopyrronium/formoterol fumarate) has been approved in Europe, as a maintenance treatment for chronic obstructive pulmonary disease (COPD).
Bevespi Aerosphere demonstrates statistically significant improvement in lung function in patients w worldpharmanews
September 26, 2017
Dr. Colin Reisner, Head of Respiratory, Global Medicines Development at AstraZeneca, said: "These positive results add to the strong established efficacy and safety profile of Bevespi Aerosphere in the treatment of patients with COPD.